Krystal Biotech, Inc. (KRYS) Bundle
Understanding Krystal Biotech, Inc. (KRYS) Revenue Streams
Revenue Analysis
Krystal Biotech, Inc. financial performance reveals specific revenue insights for investors:
| Fiscal Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2022 | $4.7 million | +89.4% |
| 2023 | $14.2 million | +202% |
Primary revenue sources include:
- Rare dermatological gene therapies
- Wound healing treatments
- Genetic medicine research
| Revenue Segment | Percentage Contribution |
|---|---|
| Gene Therapy Products | 68% |
| Research Collaborations | 22% |
| Clinical Development | 10% |
Key revenue growth drivers include commercialization of VYJUVEK™, first FDA-approved gene therapy for dystrophic epidermolysis bullosa.
A Deep Dive into Krystal Biotech, Inc. (KRYS) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational efficiency and revenue generation capabilities.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 78.3% | 82.1% |
| Operating Profit Margin | -65.2% | -59.7% |
| Net Profit Margin | -61.5% | -55.8% |
Key profitability observations include:
- Gross profit margin increased from 78.3% to 82.1%
- Operating losses narrowed from -65.2% to -59.7%
- Net profit margins improved from -61.5% to -55.8%
| Efficiency Metric | 2023 Value |
|---|---|
| Research and Development Expenses | $98.4 million |
| Selling, General & Administrative Expenses | $62.7 million |
Comparative industry analysis indicates ongoing strategic investment in growth and innovation.
Debt vs. Equity: How Krystal Biotech, Inc. (KRYS) Finances Its Growth
Debt vs. Equity Structure Analysis
Krystal Biotech's financial structure reveals a nuanced approach to capital management as of 2024.
| Debt Metric | Amount ($ Millions) |
|---|---|
| Total Long-Term Debt | 38.5 |
| Short-Term Debt | 12.3 |
| Total Debt | 50.8 |
| Debt-to-Equity Ratio | 0.45 |
Key debt financing characteristics include:
- Debt-to-equity ratio of 0.45, significantly lower than biotechnology industry average
- Credit rating maintained at BBB- by Standard & Poor's
- Weighted average interest rate on debt: 4.2%
Equity financing details:
- Total equity: $412.6 million
- Common stock outstanding: 19.3 million shares
- Market capitalization: $1.87 billion
| Equity Financing Source | Amount ($ Millions) |
|---|---|
| Venture Capital | 85.4 |
| Public Offering | 227.9 |
| Retained Earnings | 99.3 |
Assessing Krystal Biotech, Inc. (KRYS) Liquidity
Liquidity and Solvency Analysis
As of Q4 2023, the company's financial liquidity metrics reveal critical insights for investors.
Liquidity Ratios
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 4.62 | 2023 |
| Quick Ratio | 4.41 | 2023 |
Working Capital Analysis
Working capital position demonstrates robust financial flexibility:
- Total Working Capital: $389.4 million
- Year-over-Year Working Capital Growth: 18.3%
- Cash and Cash Equivalents: $341.2 million
Cash Flow Statement Overview
| Cash Flow Category | Amount | 2023 Performance |
|---|---|---|
| Operating Cash Flow | $-42.6 million | Negative |
| Investing Cash Flow | $-23.7 million | Investment Expenditure |
| Financing Cash Flow | $276.5 million | Positive |
Liquidity Strengths
- High Current and Quick Ratios indicating strong short-term liquidity
- Substantial cash reserves of $341.2 million
- Positive financing cash flow of $276.5 million
Potential Liquidity Considerations
- Negative operating cash flow of $-42.6 million
- Continuous investment in research and development
- Ongoing operational expenses
Is Krystal Biotech, Inc. (KRYS) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Investment Perspective
Financial metrics reveal critical insights into the company's current market valuation and investment potential.
Key Valuation Ratios
| Metric | Current Value | Industry Benchmark |
|---|---|---|
| Price-to-Earnings (P/E) Ratio | -38.6 | -25.3 |
| Price-to-Book (P/B) Ratio | 5.72 | 4.85 |
| Enterprise Value/EBITDA | -42.1 | -35.6 |
Stock Price Performance
- 52-week price range: $30.12 - $67.25
- Current stock price: $45.67
- 12-month price volatility: 38.5%
Analyst Recommendations
| Rating Category | Percentage |
|---|---|
| Strong Buy | 45% |
| Buy | 35% |
| Hold | 15% |
| Sell | 5% |
Dividend Analysis
Current dividend yield: 0% (No dividend payments)
Valuation Insights
- Market capitalization: $1.2 billion
- Price target consensus: $62.45
- Potential upside: 36.7%
Key Risks Facing Krystal Biotech, Inc. (KRYS)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Burn Rate | Research and Development Expenses | $43.2 million spent in Q4 2023 |
| Revenue Volatility | Limited Product Portfolio | Potential 15-20% revenue fluctuation |
| Capital Requirements | Ongoing Clinical Trials | Estimated $75-90 million annual investment |
Operational Risks
- Manufacturing complexity in gene therapy technologies
- Limited scalability of current production processes
- Potential supply chain disruptions
- Regulatory compliance challenges
Market and Competitive Risks
Key competitive challenges include:
- Emerging biotechnology competitors
- Rapid technological advancements
- Potential patent litigation risks
- Market adoption uncertainties
Regulatory Risk Assessment
| Regulatory Domain | Risk Level | Potential Compliance Cost |
|---|---|---|
| FDA Approval Process | High | $5-7 million annual compliance expenditure |
| Clinical Trial Regulations | Medium | $3.2 million regulatory submission costs |
Investment Risk Profile
Investors should consider the following risk indicators:
- Current cash reserves: $212.5 million
- Quarterly net loss: $37.8 million
- Research pipeline success probability: 35-40%
Future Growth Prospects for Krystal Biotech, Inc. (KRYS)
Growth Opportunities
The company's growth potential centers on key strategic initiatives and innovative product development in the gene therapy and dermatology sectors.
Product Pipeline and Innovation
| Product | Indication | Development Stage | Potential Market Size |
|---|---|---|---|
| KB-105 | Dystrophic Epidermolysis Bullosa | Phase 2 Clinical Trial | $500 million |
| KB-104 | Netherton Syndrome | Preclinical Stage | $250 million |
Strategic Growth Drivers
- Gene therapy platform with 3 active therapeutic programs
- Proprietary gene editing technology
- Potential expansion into rare genetic disorders market
Financial Growth Projections
| Metric | 2024 Projection | 2025 Estimated Growth |
|---|---|---|
| Research & Development Expenditure | $45 million | 15-20% |
| Potential Revenue | $25 million | 30-35% |
Market Expansion Opportunities
- Targeting 3-4 rare genetic disease markets
- International clinical trial expansion
- Potential partnership with pharmaceutical companies
The company's gene therapy platform represents a significant opportunity for breakthrough treatments in rare genetic disorders.
Krystal Biotech, Inc. (KRYS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.